Zusammenfassung
Das Auftreten eines postpartalen Hemmkörpers gegen Faktor VIII (F.VIII) stellt eine Rarität dar. Bis zum Jahre 1978 waren nur 26 Fälle in der Literatur beschrieben. Green und Lechner [1] berichten im Rahmen einer Übersicht über 215 nichthämophile Patienten mit einem Hemmkörper (HK) gegen F.VIII über 13 eigene Fälle eines postpartalen HK. Die Ursache, die zur Entwicklung eines postpartalen HK führt, ist völlig unklar. Er tritt entweder noch während der Schwangerschaft oder erst nach der Entbindung auf. Eine immunsuppressive Therapie kann zum Abfall des HK-Titers oder zu seinem völligen Verschwinden führen. Er kann aber auch trotz dieser Behandlung weiterbestehen.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Green D, Lechner K (1981) A survey of 215 non-hemophilic patients with inhibitor to factor VIII. Thromb Haemost 45:200–203
Vicente V, Alberca I, Gonzales G, Alegre A (1987) Normal pregnancy in a patient with a postpartum factor VIII inhibitor. Am J Haematol 24:107–109
Robboy SJ, Lewis SJ, Schur PH, Colman RW (1970) Circulating anticoagulants to factor VIII. Am J Med 49:742–752
Michiels JJ, Bosch LJ, van der Pias PM, Abels J (1978) Factor VIII inhibitor postpartum. Scand J Haematol 20:97–107
Voke J, Letsky E (1977) Pregnancy and antibody to factor VIII. J clin Path 30:928–932
Kasper CK (1975) A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 34:869–872
Kasper CK, Pool JG (1975) Measurement of mild factor VIII inhibitors in Bethesda units. Thromb Diath Haemorrh 34:875
Lottenburg R, Kentro TB, Kitchens CS (1987) Aquired hemophilia. Arch Intern Med 147:1077–1081
Hultin MB (1991) Aquired inhibitors in malignant and nonmalignant disease states. Am J Med 91, Suppl: 5A–9S–5A–13S
Sjamsoedin LJM, Heijnen L, Mauser-Bunschoten EP, van Geijlswijk JL, Houwelingen HV, van Asten P, Sixma JJ (1981) The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. N Engl J Med 305:717–721
Hilgartner MW, Knatterud GL, and the FEIBA study group (1983) The use of Factor VIII Inhibitor By-passing Activity (FEIBA Immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 61:36–40
Hiller E, Holler E, Geursen RG, Riess H (1986) Successful treatment with high-dose intravenous immunoglobulin in a patient with spontaneous inhibitor to factor VIII. Blut 52:123–126
Zimmermann R, Kommerell B, Harenberg J, Eich W, Rother K, Schimpf K (1985) Intravenous IgG for patients with spontaneous inhibitor to factor VIII. Lancet i:273–274
Heyman MR, Chakravarthy A, Edelmann BB, Needleman SW, Schiffer ChA (1988) Failure of high-dose i. v. gammaglobulin in the treatment of spontaneously acquired factor VIII inhibitors. Am J Hematol 28:191–194
Proctor SJ, Jackson G, Carey P, Stark A (1988) Short-course alpha-interferon therapy in severe unresponsive immune thrombocytopenic purpura. Lancet i:950
Sonnenfeld G (1984) Effects of interferon on antibody formation. In: Vilcek J, De Mayer F (eds): “Interferons and the Immune System”. Elsevier Science Publishers BV, S. 85–98
Medenica RD, Slack N (1985) Immunomodulatory activity of human leucocyte interferon in cancer patients: Results obtained during pulse therapy schedule. Cancer Drug Deliv 2:91–118
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Schwerdtfeger, R., Hintz, G., Huhn, D. (1992). Recombinantes humanes Interferon-alpha (rh IFN) zur Behandlung eines therapieresistenten postpartalen Hemmkörpers gegen Faktor VIII. In: Landbeck, G., Scharrer, I., Schramm, W. (eds) 22. Hämophilie-Symposion Hamburg 1991. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77881-0_37
Download citation
DOI: https://doi.org/10.1007/978-3-642-77881-0_37
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-56096-8
Online ISBN: 978-3-642-77881-0
eBook Packages: Springer Book Archive